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Abstract
Background: The effectiveness of collaborative care for patients with major depressive disorder in primary care has
been established. Assessing its cost-effectiveness is important for deciding on implementation. This review
therefore evaluates the cost-effectiveness of collaborative care for major depressive disorder in primary care.
Methods: A systematic search on economic evaluations of collaborative care was conducted in Pubmed and
PsychInfo. Quality of the studies was measured with the Cochrane checklist and the CHEC-list for economic
evaluations. Cost-effectiveness and costs per depression-free days were reported.
Results: 8 studies were found, involving 4868 patients. The quality of the cost effectiveness studies, according to
the CHEC-list, could be improved. Generally, the studies did not include all relevant costs and did not perform
sensitivity analysis. Only 4 out of 8 studies reported cost per QALY, 6 out of 8 reported costs per depression-free
days. The highest costs per QALY reported were $49,500, the highest costs per depression-free day were $24.
Conclusions: Although studies did not fulfil all criteria of the CHEC-list, collaborative care is a promising
intervention and it may be cost-effective. However, to conclude on the cost-effectiveness, depression research
should follow economic guidelines to improve the quality of the economic evaluations.
Background
Annually, seven percent of the adults suffer from the
consequences of depressive disorder and 16 percent
once in their lifetime [1]. In 2020, depression is
expected to rank second, after cardiovascular disease, in
terms of driving the loss of Disability Adjusted Life
Years (DALYs) [2]. Although several effective treatment
options for depression are available, their impact on the
societal burden or costs of depression remains limited
[3]. In depressive disorder, a multidisciplinary approach
for treatment may be needed, such as disease manage-
ment. Disease management programs (DMPs) organise
healthcare around a specific disease, i.e. depressive dis-
order, and provide evidence-based treatment as
described in multidisciplinary guidelines [4]. DMPs have
been proven effective for the treatment of depressive
disorder in US primary care in terms of symptom reduc-
tion, quality of life, adherence to medication and attain-
ing remission of depression [5-11]. Collaborative care
has important characteristics of a DMP and is used for
depression management in the US. It organises care
around a patient, using a care-manager to give less-
costly, qualitative good and effective care.
In a stepped-care arrangement, the intensity or com-
plexity of care is stepped-up only when proven neces-
sary. Patients are first offered an intervention that, while
likely to be effective, is relatively easy to implement and
carries relatively low cost or side effects. If the effect
turns out to be insufficient, treatment is stepped up to a
more complex, costly or taxing (in terms of side effects)
level. The aim is to ensure that all eligible patients have
access to appropriate care, while reserving the most
complex treatments for those that have demonstrated
not to benefit for more simple treatment. This strategy
can be integrated rather easily within collaborative care,
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which has proven to be an effective treatment model for
the treatment of major depression in primary care.
Overall effect sizes range from 0.25 (95% CI 0.18-0.32)
in the US [9,12,13] to 0.63 (95% CI 0.18-1.07) in the UK
health care system [14]. The longer-term (4 years) effect
size was 0.15 (95% CI 0.001-0.31) [15]. Comparing the
costs and benefits of collaborative care is necessary
when health policy makers request information on the
relative efficiency of health care programs. Two 2006
reviews [8,9] addressed presented data on collaborative
care, but described DMPs in general and collaborative
care as a part of disease management, instead of colla-
borative care alone. Also, these reviews included studies
targeted to healthcare professionals. In the present
study, only studies that provided care for patients were
included. Besides that, the mentioned reviews provided
data of studies that were published until 2005. Several
new studies have added economic information, and an
update on the collaborative care data therefore is neces-
sary. The aim of this study is to addresses the cost-effec-
tiveness of collaborative care for the treatment of major
depressive disorder in primary care.
Methods
The method of a systematic review is followed [16] and
a QUOROM flowchart is used [17]. Cost data were
synthesized using descriptive methods.
Search methods
The search on Pubmed (Medline) and PsychInfo was
conducted from October 2007 through June 2008 to
include all articles on the subject. Also, the Cochrane
Library was checked for reviews or ongoing reviews. An
update on the search was performed in October 2009.
The search was performed with the following terms:
depression, depressive disorder, collaborative care, dis-
ease management, stepped care, cost-effectiveness, cost-
utility, and cost-benefit analysis and economic evaluation.
If a review was found on the subject, the references were
checked for eligible studies. No limitations were used.
Inclusion criteria
The articles had to be a RCT or systematic review of
sufficient quality according to the Cochrane criteria
[16], and the abstract and full text of the articles had to
be available. The cost-effectiveness and, whenever possi-
ble, the cost-utility had to be presented. Patients had to
be diagnosed with major depressive disorder (MDD),
according to the Diagnostic and Statistical Manual of
Mental Disorders or International Statistical Classifica-
tion of Diseases (DSM or ICD) criteria. Articles where
co-morbidity of MDD with other diseases was studied
were accepted but the focus of the intervention had to
be on depressive disorder. Decision-analytic models
were not included in this study, as they did not report
on the cost-effectiveness of collaborative care.
The intervention had to be based on (stepped) colla-
borative care for the treatment of major depressive dis-
order in primary care. Programs were defined as
collaborative care if treatment complied with at least
three of the following criteria:
1. Within collaborative care the role of care manager
is introduced to assist and manage the patient by
providing structured and systematic interventions.
2. A network is formed around the patient with at
least two of the three following professionals: general
practitioner, care manager, and consultant psychia-
trist, a definition provided by Katon et al [18,19].
3. Process and outcome of treatment is being moni-
tored and in case of insufficient improvement treat-
ment may be changed according to the principles of
stepped care [4].
4. Evidence-based treatment is provided [4].
Data analytic procedures
Data abstraction
The abstracts of selected articles that seemed relevant
for this review were retrieved and read by two indepen-
dent reviewers. Based upon the inclusion criteria, they
both selected eligible articles. After that, the full text
was read and a selection of eligible articles was made. In
case of disagreement, a third reviewer decided on the
inclusion of the article. When the two independent
reviewers both accepted a study, the Cochrane checklist
for quality assessment of articles was used [16] to rate
the quality of the studies independently and in duplicate.
With this checklist, studies can be rated on the presence
of randomization and concealment of allocation, the
blinding of patients, care providers and outcome asses-
sors, mentioning drop-out and performing an intention-
to-treat analysis.
Also, the CHEC-list [20] for economic evaluations was
used to assess the quality of the cost-effectiveness mea-
surements. In this CHEC-list, 19 points can be scored
when aspects are properly addressed in the article, for
instance a good description of the study population, the
intervention and competing alternatives, the research
question and the perspective from which the costs and
effects are measured and whether relevant costs are
measured, relevant outcomes are defined, an incremen-
tal analysis is performed, the generalizability is discussed
and a sensitivity analysis is performed. A well performed
economic evaluation adequately addresses all 19 items
in the article.
Effects
The effects were measured with validated depression
scales e.g. the Hamilton Rating Scale for Depression
(HRSD), the Hopkins Symptom checklist (HSCL) or the
Montgomery Åsberg Depression Rating Scale (MADRS).
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More general effect measurements included Quality
Adjusted Life Years (QALYs) and days absence from
work.
Costs
Preferably, costs are measured from a societal perspec-
tive, including all relevant costs for society. The societal
costs can be divided into direct medical costs e.g. outpa-
tient costs, medication and hospital days, direct non-
medical costs e.g. travelling costs, and indirect non-
medical costs e.g. the costs caused due absence of work
and total costs. The costs can be measured from tariffs
(billed charges), or actual costs. Tariffs are the maxi-
mum costs that for example a specialist may charge for
a consult, actual costs are the costs a specialist makes
for each consult including personnel and overhead. All
costs were measured in US dollars, or converted to US
dollars if necessary, using the currency rate at the time
the study was performed. There was no adjustment for
different financial years.
Cost-effectiveness
Costs per QALY is the preferred unit for measuring
cost-effectiveness. This is an international used mea-
surement with accepted cut-off points. A UK approach,
by Devlin & Parkin [21], states that a new intervention
is cost-effective when it costs a maximum of £20,000 -
£30,000 per Quality Adjusted Life Year (QALY);
approximately US $34,000 - $51,000. In depression-
management it is usual to measure the costs per depres-
sion-free day (DFD) or the costs per successfully treated
patient. However, there is no consensus about the socie-
tal accepted value of a DFD.
Analyses
First, the studies were assessed according to the CHEC-
list for economic evaluations [20]. Subsequently, effect
measurements, cost components, perspectives and cost-
effectiveness ratios were derived from the studies,
reported in values of the same year of the trials. Find-
ings of cost-effectiveness were presented in a permuta-
tion matrix, adopted from Nixon et al [22]. In this
permutation matrix, the costs and effects of the inter-
vention group are compared with the costs and effects
of the control group. The results are reported in a
descriptive manor, only showing the most striking
results, as there were too many to report all and too dif-
ferently measured to aggregate them.
Results
Study selection
In figure 1, a flowchart of the study selection is pre-
sented [17].
From the initial search (336 abstracts), 26 studies were
selected based on the abstracts. Based on full text exam-
ination, 18 studies were excluded; 4 were study-proto-
cols, 13 did not meet the inclusion criteria and 1 was a
systematic review that reviewed articles in our selection.
All studies fulfilled the preset criteria for treatment
according to collaborative care. All eight remaining stu-
dies were deemed of sufficient quality, as shown in table
1[23-30] There was no disagreement between the two
assessors. Using the 19-item CHEC-list [20] the
included studies were assessed on quality of performed
economic evaluations. A maximum of 10 points out of
19 was scored, as shown in table 2.
In total, eight studies were included, all providing cost-
effectiveness analyses of a collaborative care intervention
for the treatment of major depressive disorder. While
this was not a restriction, all studies were performed in
primary care [23-30]. Except for two [23,24], all studies
measured the treatment effect using average depression-
free days. The costs were measured and presented in
direct medical costs and direct non-medical costs. Four
studies analysed both cost-effectiveness and cost-utility
[24-26,29], the other studies performed a cost-effective-
ness analysis not considering QALYs [23,27,28,30].
Study outcomes
The main findings of the included studies are summar-
ized in table 3.
Demographic variables
The population as described in the included studies, has
the following characteristics. One study[29] included
patients aged 60 or more; other studies covered a gen-
eral adult population. The mean age reported varies
from 40 to 71.2 years old.
The total amount of participants (all eight studies
combined) was 4868 and the lowest number reported in
one study was 145. One included a veteran population,
mainly consisting of males (95%) [27] and one study
investigated the collaborative care intervention for
patients with major depressive disorder and diabetes
mellitus[30]. Seven studies were performed in the Uni-
ted States [23-27,29,30] and one was performed in Chile
[28]. All studies fulfilled the criteria for collaborative
care and all studies compared collaborative care to care
as usual in primary care.
Effects
Depression-free days
Most of the studies reported depression-free days as the
primary outcome measure [24,25,27-30]. These were
calculated by using the Hamilton Rating Scale for
Depression (HRSD) where a score equal or less to 7 is a
depression free day [24,28]. Others used the Symptom
Checklist (SCL-90 or HSCL-20) where a score of .5 or
less is considered depression free [25,27,29,30]. Both
‘translations’ into depression free days are reported by
Lave et al [31]. The follow-up of the included studies
varied from 6 months to 24 months.
The study by Liu et al [27] reported an increment in
depression-free days of 14.6 in a nine-month follow-up,
van Steenbergen-Weijenburg et al. BMC Health Services Research 2010, 10:19
http://www.biomedcentral.com/1472-6963/10/19
Page 3 of 10
while the other studies reported 20 to 60 more depres-
sion-free days in the first year of the follow-up, com-
pared to the control group [24,28-30]. In the second
year of the follow-up, the intervention group reported
33 to 56 more depression-free days compared to the
control group [28-30].
Two studies reported reductions in SCL-score [23,27]
but only one [23] reported numbers: a 50 percent reduc-
tion for the intervention group. For the care as usual
group, a 40 percent reduction was reported [23]. Liu et
al [27] only reported that there was a significant reduc-
tion in SCL-score at three months (P < .025), at 9
months there was no significant effect.
QALYs
Four studies reported QALYs next to depression-free
days, over a average period of 6 months. In three studies
[24,25,29] these were calculated based on the change
from the HRSD-score or SCL-score. The improvement
from depression to remission was associated with an
improvement of 0.2-0.4 in the measure of QALY, as
Figure 1 Flowchart (Moher et al [17]).
Table 1 Quality assessment of the RCTs by using the Cochrane Quality checklist[16].
Article Quality grade (out of 7) By reviewer: Article included/excluded
KW CFC
Von Korff et al[23] 4 4 Included
Simon et al[24] 5 5 Included
Simon et al[25] 6 6 Included
Schoembaum et al[26] 4 4 Included
Liu et al[27] 4 4 Included
Araya et al[28] 4 4 Included
Katon et al[29] 4 4 Included
Simon et al[30] 5 6 included
Cochrane Quality Checklist: randomized allocation of participants, concealed treatment allocation, blinded patients, blinded caregivers, blinded outcome
assessors, drop-out rate acceptable, intention-to-treat analysis performed.
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defined in previously performed cost-utility studies
[32-34]. The number of QALYs calculated with this
method varied from 0.05 [23] to 0.117 [29]. Schoen-
baum et al [26] calculated QALYs in two ways: from
the Short Form-36 (SF-36) and the depression-burden
(DB) days. The amount of QALYs were derived from a
sample of primary care patients with symptoms of
depression, using a standard gamble approach [26]. The
SF-36 method calculated an increase in QALYs of
0.0226 (P = .006) due to the intervention and the DB
method calculated an increase of 0.0258 to 0.0515
QALY, according to Schoenbaum et al [26].
All studies claimed that collaborative care for the
treatment of depressive disorder is more effective than
care as usual in terms of depression-free days and
QALYs.
Costs
Direct medical costs
Most studies were conducted from a health care per-
spective, only two included production losses and travel-
ling expenses. The studies were performed in primary
care and reported health service use in primary care,
outpatient specialty mental healthcare and admissions,
as reported in table 4. The costs were measured by mul-
tiplying the measured healthcare usage and the charges
for these healthcare services. Across the various studies,
this is done by self-reported healthcare service usage
[26,28], by records of patient contacts [23,27,29], com-
puterized health plan data [24,25,30].
Four studies mentioned intervention related costs. In
the study by Katon et al [29] the increment in interven-
tion related direct medical costs was $921 per person
for a two year follow-up, compared with CAU.
Simon et al [30] reported intervention related direct
medical costs over 2 years of $21,148 (SD $27,548) for
the intervention group vs. $22,258 (SD $35,607) for the
control group, a saving of $1,110.
In the study by Liu et al [27] the increment in inter-
vention related direct medical costs was $519 for the
intervention group, compared with CAU.
The study by Simon et al [24] reported an increment
in intervention related direct medical costs of $675. For
outpatient costs (all contacts with medical or ancillary
providers and medications) and inpatient health services
costs (hospitalization, inpatient services and procedures,
medications) together, the increment was $1,974.
Direct non-medical costs
In the study by Simon et al and Schoenbaum et al
[24,26], the follow-up assessments also included the
time costs (including travel and waiting time), for
obtaining healthcare. The time for outpatient medical
and mental health visits was, respectively, 30 and 45
minutes [26].
The travelling expenses varied from $1,636 (95% CI
$1,356-$1,916) for the intervention group to $1,337
(95% CI $1,174-$1,499) for the CAU group [24].
Indirect non-medical costs
One study reported production losses, measuring the
days worked in 6 months and the days missed from
work due to illness [26]. There was a significant inter-
vention effect on days worked overall, but the amount
of sick days among workers did not statistically differ
between the intervention and usual care patients. None
of the included studies had quantified the production
losses into costs.
Cost-effectiveness
All studies found that collaborative care is effective but
in most cases also more expensive than CAU
[23-27,29,30]. In one study, the total outpatient costs in
the first year of the follow-up were higher compared to
care as usual. However, in the second year of follow-up
costs of the intervention were lower [30]. Another study
[28], conducted in Chile, collaborative care was signifi-
cantly more effective and marginally more expensive
than usual care after 6 months of follow-up.
Six studies reported the intervention related direct
medical costs per depression-free day [24,25,27-30]. The
increment in costs for the intervention group compared
with the control group varied from $20 to $24 per
depression free day [24,27]. The incremental cost-effec-
tiveness ratio (the healthcare costs per depression-free
day) was reported by Katon et al [29] at 2.76. One study
included other direct medical costs (medications, total
medical consultations, healthcare usage) [28] and calcu-
lated the incremental cost-effectiveness ratio at 0.75 in
Chilean Pesos.
Von Korff et al [23] reported the costs per successfully
treated patient, in this case a 50% or greater reduction
in SCL-score at 4-month follow-up. The average costs
per successfully treated patient were $1,797 for the
intervention group vs. $1,941 for the control group.
Table 2 Quality assessment of the economic evaluations
by using the 19-item CHEC-list[20].
Study Score on the 19-point CHEC-list for
economic evaluations
KW LH
Von Korff et al[23] 6 5
Simon et al[24] 7 6
Simon et al[25] 9 6
Schoenbaum et al[26] 9 7
Liu et al[27] 7 6
Araya et al[28] 9 7
Katon et al[29] 8 5
Simon et al[30] 10 9
CHEC-list: study population, competing alternatives, research question,
perspective, relevant costs, relevant outcomes, incremental analysis,
generalizability, sensitivity analysis.
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Table 3 Cost-effectiveness of primary care interventions based on collaborative care.
First author Population Accepted as CC because: Cost measurement Effectiveness
measurement
Results
Von Korff et al,
1998[23]
Prices based
on the year:
unknown
Primary care patients
(US), newly diagnosed
major depression (DSM-
III-R), N = 153
Mean age: I = 43.1, C =
44.8
Collaborative management,
psychologist and physician,
problem-solving treatment
Health care
perspective
Intervention costs,
primary care costs
Follow-up: 7 months
SCL-90 score,
successfully
treated case of
depression
Incremental cost-effectiveness:
$3741 per successfully treated
case of major depression.
Reduction in SCL-score (70.4%
vs. 42.3%)
Conclusion: strong indication
for cost-effectiveness
Simon et al,
2001a[24]
Prices based
on the year:
1996
Patients not responding
to 8 weeks usual care,
US primary care, major
depression according to
DSM-IV, N = 228
Mean age: I = 45.6, C =
45.4
Stepped care, patient
education, advice to patient
and physician by psychiatrist,
ongoing management
Social perspective
Intervention costs,
non-depression
primary care costs,
total out-patient
treatment costs, total
health service costs
Follow-up: 6 months
SCL-90 score,
HRQoL
Incremental intervention
related direct medical costs:
$21 per DFD (95% CI $8 to
$126) over 6 months.
Total healthcare costs $35 per
DFD (95% CI -$52 to $388)
over 6 months.
Patient costs: travelling
expenses I = $1636 (95% CI
1356-1916) C = 1337 (95% CI
1174-1499)
I = 50% reduction SCL score,
95% CI 1.02 - 2.03.
Conclusion: strong indication
for cost-effectiveness
Simon et al,
2001b[25]
Prices based
on the year:
unknown
High utilisers of medical
care, high probability of
undiagnosed major
depression (DSM-IV), US
primary care, N = 407.
Mean age: I = 47.2, C =
46.7
Depression management
coordinated by primary care
mental health worker,
psychiatrist support, physician
and patient education, using
guidelines
Health care
perspective
Intervention costs, in-
and outpatient
depression treatment
costs
Follow-up: 12 months
HRSD
improvement,
HRQoL,
Intervention related direct
medical costs $21 (95% CI $11
to $38) per DFD.
HRSD: 53.2% (I) vs. 32.8% (C)
shows 50% improvement
after 12 months
Conclusion: strong indication
for cost-effectiveness
Schoenbaum
et al, 2001[26]
Prices based
on the year:
1998
US primary care, major
depression according to
DSM-IV, N = 1356
Mean age: I = 44.5, C =
42.2
Nurse specialists follow-up
patients, conjunction
between nurse - primary care
physician and specialist
Health care
perspective
Depression primary
care costs, intervention
costs, costs per QALY
Follow-up: 24 months
HRQoL (QALYs
calculated from
SF-12 and
Depression
burden days),
CES-D
Intervention related direct
medical costs by SF-12
method $21 478 per QALY
(confidence interval not
given). By DFD method, 95%
CI $9478 to $18 953
CES-D reduction: 50% for
intervention.
Conclusion: strong indication
for cost-effectiveness
Liu et al, 2003
[27]
Prices based
on the year:
2000
Veteran population, Male
= 95%, Major depression
according to DSM-IV, N
= 354
Mean age: I = 57.8, C =
56.6
Patient education, progress
evaluation, team meetings,
stepped care
Health care
perspective
Total (outpatient) costs
Follow-up: 9 months
SCL-90 score DFD increment for I = 14.6
Intervention related direct
medical costs: I = $615
higher, $3754 (CI 3329-4179)
vs. $3139 (CI 2759 -3519).
Total intervention costs: I =
$1259 higher; $7946 (CI 5582-
10310) vs. $6789 (CI 4720-
8858).
I = SCL sign. better at 3
months (P < .25)
Conclusion: strong indication
for cost-effectiveness
Araya et al,
2006[28]
Prices based
on the year:
2004
Females 18-70 years,
major depression
according to DSM-IV, N
= 240
Mean age: I = 44.1 (SD
12.1) and C = 42.0 (SD
13.7)
Monitoring clinical progress,
manager coordinates with
physicians, stepped care
Health care
perspective
Costs per patient, cost-
effectiveness ratio
Follow-up: 6 months
HRSD score DFD: I = 50 more. Incremental
cost-effectiveness ratio = 0.75.
Intervention related direct
medical costs: I = $87.8 per
patient (CI 78.9 - 103.4), C =
$51.5 per patient (CI 43.0 -
60.5)
Conclusion: cost-effective
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Cost- utility
Four studies presented cost-utility ratio’s in which incre-
mental costs per QALY were estimated [24,26,28,29].
The direct medical costs per QALY are divided into
intervention costs and healthcare costs. The intervention
costs varied from $2519 (95% CI -4,517 - $9,554) to
$5037 (95% CI -$9,034 to $19,108) [29]. The direct- and
indirect costs per QALY together were $21,478 [26].
Simon et al [24] measured the costs per QALY at
$49,500. The findings are summarized in figure 2, where
the costs and effects for the intervention group (in com-
parison with the control group) per study are compared.
Discussion
The included studies scored a maximum of 10 points
out of 19 on the CHEC-list, indicating that the quality
of the studies can be improved. Studies on the cost-
effectiveness of collaborative care indicate that this type
of intervention for the treatment of MDD in primary
care can be cost-effective, relative to usual care,
Table 4 Incremental costs and depression-free days.
Study Incremental DFDs
for CC vs. CAU
Incremental costs for
CC vs. CAU in US$
Costs measurement
Von Korff et al
[23]
None reported 3741 Intervention costs, primary care costs (average direct and overhead costs to the
health maintenance organization)
Simon et al
[24]
47.4 1640 Total health services costs (anti-depressants, outpatient specialty services,
inpatient services, intervention costs)
Simon et al
[25]
16.8 296 Health services costs (outpatient costs, inpatient costs mental health specialty
costs, medications, visits CC psychiatrist)
Schoenbaum
et al[26]
None reported 485 Intervention costs, healthcare costs (emergency department visits, medical and
mental health visits, and psychotropic medications used)
Liu et al[27] 14.6 1157 Total health services costs (antidepressants, primary care visits, mental health
specialty care, intervention program costs)
Araya et al[28] 50 36.4 Total health services costs (Medical consultation costs, medication use, use of
health services, intervention costs)
Katon et al[29] 107 (2 years follow-
up)
921 (two years follow-up) Total health services costs (anti-depressants, intervention costs, outpatient
specialty mental health care costs)
Simon et al
[30]
20 26 Total outpatient costs (outpatient depression treatment costs and outpatient
non-depression treatment costs)
DFD = depression-free day; CC = collaborative care; CAU = care as usual.
Table 3: Cost-effectiveness of primary care interventions based on collaborative care. (Continued)
Katon et al,
2005[29]
Prices based
on the year:
unknown
Diabetes, major
depression according to
DSM-IV, N = 1801
Mean age: I = 71, C =
71.4
Based on IMPACT protocol,
stepped care, depression care
manager consults with
professionals, problem-solving
treatment
Health care
perspective
Outpatient mental
health costs, costs per
QALY
Follow-up: 24 months
HSCL-20
improvement,
QALYs
Increment in DFD 1st year:
52.6 (CI 42.2 - 63.0). Increment
in DFD 2nd year: 54.3 (CI 42.2
- 66.2). Intervention related
direct medical costs 2nd year
follow-up = $921 higher than
CAU. Costs per QALY: $2519
(95% CI -$4517 to $9554)) to
$5037 (95% CI -$9034 to $19
108).
Conclusion: strong indication
for cost-effectiveness
Simon et al,
2007[30]
Prices based
on the year:
unknown
Diabetes and major
depression according to
DSM-IV, N = 329
Mean age: I = 58, C = 57
Stepped care, depression
nurse coordinates contacts
with professionals and
patient, treatment based on
the IMPACT-model
Health care
perspective
Outpatient costs
Follow-up: 24 months
SCL-90 score Increment in DFD: I = 20 in
1st year, 33 in 2nd year.
Intervention related direct
medical costs costs: I = $1400
lower in 2nd year, mean I =
$600 lower in 2nd year.
Health services in 2 years: I =
$21148 (SD 27548) vs. C =
$22258 (SD 35607)
Conclusion: strong indication
for cost-effectiveness
C = control, CC = collaborative care; CE = cost-effectiveness; CES-D = Centre for Epidemiologic Studies-Depression scale; DFD = depression free days; DSM =
diagnostic and statistical Manual of mental disorders; E = effectiveness; HRQoL = health related quality of life; HRSD = Hamilton Rating Scale for Depression;
HSCL-20 = Hopkins symptom checklist -20; I = intervention; MADRS = Montgomery Åsberg depression rating scale; PRIME-MD = primary care evaluation of
mental disorders; QALY = quality adjusted life year; SCL-90 = Symptom checklist - 90; SF-12 = Short Form
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depending on willingness to pay. The collaborative care
patients have 60 more depression-free days than care as
usual patients, and in the second year of the follow-up
this is 56 depression-free days. For the collaborative
care interventions on the treatment of depressive disor-
der, the reported incremental costs per QALY were
$21,478 to $49,500 for all the costs of healthcare ser-
vices together.
But to determine the cost-effectiveness of collaborative
care, it is necessary to compare the costs of the inter-
vention with the benefits. What can be helpful is to look
at previously performed studies of which the interven-
tion has been implemented. For example the study of
Devlin and Parkin [21], where they compare studies that
have been implemented by the NICE institute in Great
Britain. They concluded that when the costs per QALY
did not exceed the maximum of $51,000, the study was
implemented [21].
Unützer et al [15] have reported the long term costs
of collaborative care treatment. In a 4-year follow-up of
551 patients the direct medical costs (here the costs of
the intervention, outpatient costs, pharmacy costs and
inpatient costs together) were measured. The interven-
tion group accounted for $29,422 (95% CI $26.479 -
$32,365) versus $32,785 (95% CI $27.648 - $37.921) for
the control group; a difference of $3,363 in favour of
the intervention group.
Limitations of the study
The quality of the economic evaluations was assessed
with the CHEC-list [20]. Items on the CHEC-list that
scored low were among others the performance of sensi-
tivity analysis and the usage of QALYs. Costs of sick
leave were only measured in one study, while studies
showed that productivity costs are responsible for a
majority of the costs [35,36]. Also, studies were only per-
formed for a maximum of 6 months, which leaves the
long-term consequences unknown. Unfortunately only 4
out of 8 studies considered the costs per QALY. Future
studies on the cost-effectiveness of collaborative care
should be performed according to an economic guideline
to have good quality studies [37]. The $51,000 cut-off
point for costs per QALY is not optimal as this is a UK
recommendation while most studies were performed in
the US. Every country that wants to implement collabora-
tive care has to define itself which cut-off point they use,
based on the willingness to pay of their citizens.
Furthermore, younger adults were underrepresented in
the review as most studies described an older population
 Decision strongly favoured (B= Reject treatment, C= Accept treatment) 
 No obvious decision (Is the effect worth the costs?) 
Figure 2 Permutation matrix for the cost-effectiveness of collaborative care vs. care as usual. (Adopted from Nixon et al [22]).
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(with a minimum age of 50 years old). Because of the
population, indirect non-medical costs were not mea-
sured as they were relatively irrelevant in the medically
ill, elderly or war veteran groups. However, the average
clinical population is typically in their mid 40’s, so it
affects the generalizability of these study results to the
average population. The assessment of the direct non-
medical costs (traveling expenses) and indirect non-
medical costs (production losses) needs to be improved.
Also, the follow-up of the studies varied and this may
cause a difference in costs. All this may have a signifi-
cant impact on the total costs [33].
Thirdly, most studies are conducted in the US, in a
MCO or at Kaiser Permanente departments in different
parts of the US. This may affect the generalizabiliy of
the studies to other countries or healthcare systems.
Several European countries (the Netherlands and Hun-
gary for instance) have reformed their health care sys-
tem recently, and it can be very interesting to see if
collaborative care is cost-effective in these healthcare
systems. Also, all studies were performed in primary
care, but the question is how it will translate to for
instance the general hospital.
Finally, the definition of collaborative care is not uni-
form. Not every study labelled their intervention colla-
borative care, but they did meet the inclusion criteria of
collaborative care. It merits recommendation to make
one definition to make future research comparable.
Conclusions
Collaborative care seems a promising option to deliver
the right treatment for patients with major depressive
disorder. However, the economic information is insuffi-
cient for policy decisions. The number of studies on
cost-effectiveness of collaborative care is still limited
and the quality of these economic evaluations should be
improved. For example, only a limited number of stu-
dies presented the cost-effectiveness in terms of costs
per QALY and generally costs-effectiveness was reported
as the costs per DFD. Information on the (cost-) effec-
tiveness of CC in other settings than primary care is
needed before CC can be broadly implemented.
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